Citius Pharmaceuticals, Inc. (CTXR)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 3.9M | 1.7M |
| Gross Profit | 3.2M | 1.3M | ||
| Operating Income | -8.8M | -8.4M | -9.0M | -32.2M |
| Net Income | -8.8M | -8.0M | -8.2M | -21.2M |
| Diluted EPS | $-0.80 | $nan | $-0.38 | $-0.95 |
Annual Financials
| Metric | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -33.3M | -36.7M | -42.0M | -38.5M |
| Net Income | -33.6M | -32.5M | -39.1M | -37.4M |
| Diluted EPS | $-5.75 | $-5.57 | $-5.97 | $-3.38 |